Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
5.98
-0.27 (-4.32%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.97 - 6.38
52 week 3.10 - 7.84
Open 6.21
Vol / Avg. 767,059.00/1.01M
Mkt cap 415.94M
P/E 125.71
Div/yield     -
EPS 0.05
Shares 69.56M
Beta 1.58
Inst. own 83%
Mar 11, 2015
Q4 2014 Progenics Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 10, 2015
Progenics Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference - 3:00PM EST - Add to calendar
Jan 12, 2015
Progenics Pharmaceuticals Inc at JPMorgan Healthcare Conference
Nov 24, 2014
Progenics Pharmaceuticals Inc at Brean Capital's Life Sciences Summit Conference
Nov 20, 2014
Progenics Pharmaceuticals Inc at Jefferies Global Heatlhcare Conference - London
Nov 18, 2014
Progenics Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 7, 2014
Q3 2014 Progenics Pharmaceuticals Inc Earnings Release
Nov 7, 2014
Q3 2014 Progenics Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 88.76% -541.49%
Operating margin 88.19% -546.68%
EBITD margin - -534.74%
Return on average assets 97.41% -44.61%
Return on average equity 126.74% -58.50%
Employees 69 -
CDP Score - -

Address

777 Old Saw Mill River Road
TARRYTOWN, NY 10591
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc. is a medicine developing company. The Company is engaged in developing medicines for oncology. Its focus for Progenics is targeted therapeutics and imaging agents. The Company�s clinical development efforts center on late-stage oncology assets. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. The Company�s product, Relistor, is a treatment for opioid-induced constipation (OIC). PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a Phase 2 radiotherapeutic product candidate in development as a treatment for pheochromocytoma.

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Robert J. Israel M.D. Executive Vice President - Medical Affairs
Age: 57
Bio & Compensation  - Reuters
John W. Babich Ph.D. Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 61
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Senior Vice President - Operations and Portfolio Management
Age: 57
Bio & Compensation  - Reuters
Angelo W. Lovallo Jr., CPA Vice President - Finance, Treasurer
Age: 48
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 60
Bio & Compensation  - Reuters
David E. Martin J.D. General Counsel
Age: 59
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters